Nasus Pharma Ltd. (NSRX) closed at $2.29 on November 20, 2026, down 10.2% from the previous close, on volume of 33,141 shares (30-day average 15,751).
Data as of November 20, 2026.
Maxim Group Sticks to Their Buy Rating for Nasus Pharma Ltd. (NSRX)
TipRanks (Wed, 18-Nov 12:55 PM ET)
Globe Newswire (Tue, 17-Nov 8:00 AM ET)
Nasus Pharma Appoints Nir Sassi as Chief Financial Officer
Globe Newswire (Mon, 16-Nov 8:00 AM ET)
Nasus Pharma Announces Abstracts Accepted for Presentation at ACAAI 2026
Globe Newswire (Tue, 10-Nov 8:00 AM ET)
Globe Newswire (Tue, 29-Sep 8:00 AM ET)
Globe Newswire (Mon, 14-Sep 8:00 AM ET)
Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Globe Newswire (Tue, 8-Sep 7:30 AM ET)
NSRX’s Phase 2 Study: NS002 Delivers Epinephrine Twice as Fast as EpiPen® in Critical Minutes
Market Chameleon (Mon, 16-Mar 3:51 AM ET)
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.
Nasus Pharma Ltd. trades on the AMEX stock market under the symbol NSRX.
As of November 20, 2026, NSRX stock price declined to $2.29 with 33,141 million shares trading.
NSRX has a market cap of $26.82 million. This is considered a Sub-Micro Cap stock.
NSRX has underperformed the market in the last year with a price return of -67.3% while the SPY ETF gained +6.9%. NSRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -40.5% and -18.8%, respectively, while the SPY returned -9.3% and -6.2%, respectively.
NSRX support price is $2.38 and resistance is $2.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NSRX shares will trade within this expected range on the day.